通过整合抗逆转录病毒药物专利推动技术发展：来自中国的愿景。

Technology Development Through Pooling ARV Drug Patents: A Vision from China.

作者信息

Liu Li, Lu Hongzhou

机构信息

Department of Infectious Disease, Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai, 201508, China.

出版信息

Open AIDS J. 2010 Jan 19;4:54-9. doi: 10.2174/1874613601004020054.

DOI:10.2174/1874613601004020054

PMID:20224635

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2831193/

Abstract

Unaffordable prices still bar the end-users in China from accessing ARV drugs. Patent protection of ARV drugs has dramatically limited the availability of these lifesaving drugs to AIDS patients in China.The way Chinese government can go to breakthrough the ARV drug patents are suggested as:Make more generic drugs available through compulsory licensing, impartment from other countries or building ARVs plants by partnerships between governments or generic drug companies.Do a thorough and detailed research on the patent application of ARV drugs to find out the loophole.Try patent pool to make AIDS medicines more affordable and appropriate for patients.

摘要

高昂的价格仍然阻碍中国的终端用户获得抗逆转录病毒药物。抗逆转录病毒药物的专利保护极大地限制了这些救命药物在中国艾滋病患者中的可及性。建议中国政府突破抗逆转录病毒药物专利的途径为：通过强制许可、从其他国家进口或政府与仿制药公司合作建立抗逆转录病毒药物工厂来提供更多仿制药。对抗逆转录病毒药物的专利申请进行全面而详细的研究以找出漏洞。尝试专利池以使艾滋病药物对患者来说更可承受且更适用。